INTC vs MRK: Which Is the Better Buy?
Side-by-side comparison of Intel Corp. and Merck & Co., Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-15.
Intel Corp. · Technology
$107.76
-5.2% upside to fair value
Grade D
VS
Merck & Co., Inc. · Healthcare
$113.87
-12.1% upside to fair value
Grade D
High Quality
QuantHub Verdict
INTC has more upside to fair value
(-5.2%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
INTC |
MRK |
| Current Price |
$107.76 |
$113.87 |
| Fair Value Estimate |
$102.16 |
$100.14 |
| Upside to Fair Value |
-5.2%
|
-12.1%
|
| Market Cap |
$541.6B |
$281.2B |
| Forward P/E |
-173.8x
|
32.0x
|
| EV / EBITDA |
49.9x
|
17.3x
|
| Price / Sales |
10.1x
|
4.3x
|
| Price / FCF |
-173.7x
|
19.9x
|
| Revenue Growth YoY |
+7.2%
|
+4.3%
|
| Gross Margin |
35.4%
|
75.9%
|
| Operating Margin |
-9.4%
|
27.6%
|
| Return on Equity |
-3.0%
|
17.9%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
—
|
5.02%
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
Intel Corporation is a leading semiconductor company operating in the technology sector, specializing in designing and manufacturing microprocessors and related technologies. The business quality is currently low due to negative earnings growth of 354.1% in the most recent quarter and negative profitability metrics including a net margin of -5.9% and an operating margin of -9.4%. Despite a revenu…
Merck & Co., Inc. is a leading global healthcare company specializing in pharmaceuticals, vaccines, and animal health products. Its business quality is high, supported by a durable competitive moat anchored in the dominant global position of Keytruda in PD-1/PD-L1 oncology, a strong vaccines portfolio including Gardasil, and scale in R&D and manufacturing. The company benefits from a seasoned lea…
Accumulation Zones
| Metric |
INTC |
MRK |
| Zone Low |
$76.62 |
$75.11 |
| Zone High |
$86.84 |
$85.12 |
| In Buy Zone? |
No
|
No
|